Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis.
Phase of Trial: Phase III
Latest Information Update: 15 Jul 2014
At a glance
- Drugs LAS 41007 (Primary) ; Diclofenac/hyaluronic-acid
- Indications Actinic keratosis
- Focus Registrational; Therapeutic Use
- Sponsors Almirall S.A.
- 23 Jul 2012 Status changed from recruiting to completed, according to the ClinicalTrials.gov record.
- 31 Dec 2010 New trial record